Publications by authors named "Mona M Hosseini"
Article Synopsis
- IRAK1 is a key player in innate immunity and is found to be overactive in various cancers, including acute myeloid leukemia (AML), where it helps leukemia cells survive.
- The study showed that blocking IRAK1 using the multikinase inhibitor pacritinib significantly decreased leukemia burden in AML models, highlighting its potential as a therapeutic target.
- Pacritinib effectively inhibits IRAK1 alongside other kinases and demonstrated a strong impact on AML cells with diverse genetic mutations, suggesting its broader applicability in treating different AML subtypes.
